Abstract
Abstract

22
The methylation status of the O(6)-methylguanine-DNA methyltransferase (MGMT) gene is 23 an important predictive biomarker for benefit from alkylating agent therapy in glioblastoma. the original cut-off for various optimization criteria and for most data preprocessing methods. 36 Finally, we propose a R package mgmtstp27 that allows prediction of the methylation status 37 of the MGMT promoter and calculation of appropriate confidence and/or prediction intervals. 38 Overall the MGMT-STP27 is a robust model for MGMT classification that is independent of 39 tumor type, and is adapted for single sample prediction. properties and prognostic value (kappa=0.85; logrank p<0.001), and has been successfully 74 validated in independent datasets including clinical trials, by us and other groups 2, 9, 11, 14, 15 .
75
The original preprocessing procedure was based on the conversion of the Red/Green channel 76 from the Illumina methylation array into the methylation signal, without using any 77 normalization. However, the rising interest into epigenetics has stimulated development of 78 methods to analyze DNA methylation data including numerous procedures for normalization 79 and bias correction [16] [17] [18] [19] . Triche et al. 17 listed no fewer than seven methods to correct dbGaP accession number to the specific version of the TCGA data set is phs000178.v9.p8.
120
The datasets and their accession numbers, including their corresponding expression datasets, 121 are described in detail in the Supplemental Table S1 . The clinical and molecular baseline 122 description for the glioma datasets is summarized in Supplemental Table S2 . 
Results
195
Epigenetic context of MGMT promoter methylation and expression of MGMT
196
The fact that almost all CIMP+ glioma are predicted to have a methylated MGMT status using can affect the robustness of the statistical tests (Table 2 ).
262
The interaction between deletion and methylation was not significant ( Table S3 and Supplemental Figure S5 ) in the LGG populations 269 and it was not reasonably testable in the GBM populations considering the very low 270 frequency of this event (7%, Supplemental Table S2 ).
272
Effect of tumor matrix (frozen versus FFPE)
273
The beadchip platform can be used for frozen and with the addition of a restoration step also 274 for formalin fixed paraffin embedded (FFPE) samples. Here we tested whether datasets 275 originating from different sample matrices can be combined. The VB-Glioma-III dataset, 276 containing 51 frozen samples and 59 FFPE samples, was analyzed (Supplemental Table S1 ).
277
The distributions of the MGMT scores calculated for FFPE and frozen samples, respectively, and one (1.5%) reclassified samples were detected for TCGA-GBM-450 and M-GBM, 296 respectively (Supplemental Table S4 ). In contrast, the concordance between the initial 297 classification and outputs resulting from a procedure using quantile normalization separately 298 on each signal was extremely low ( Figure 5C and Supplemental Figure S7C ), indicating 299 incompatibility between this procedure and the current MGMT-STP27 default parameters. 
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